• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估血浆外泌体 miRNA 作为甲状腺乳头状癌淋巴结转移的潜在诊断生物标志物。

Evaluation of plasma exosomal miRNAs as potential diagnostic biomarkers of lymph node metastasis in papillary thyroid carcinoma.

机构信息

Thyroid Surgery Center, West China Hospital of Sichuan University, Chengdu, 610041, China.

Laboratory of Thyroid and Parathyroid Disease, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.

出版信息

Endocrine. 2022 Mar;75(3):846-855. doi: 10.1007/s12020-021-02949-x. Epub 2021 Dec 1.

DOI:10.1007/s12020-021-02949-x
PMID:34854020
Abstract

PURPOSE

The early diagnosis of lymph node metastasis (LNM) in papillary thyroid carcinoma (PTC) is clinically important, as it can aid in treatment decision-making and improve prognosis. In the present study, we aimed to identify whether plasma exosomal miRNAs could be potential diagnostic markers of LNM in PTC.

METHODS

Profiles of plasma exosomal miRNAs were screened using miRNA microarrays. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was performed in the validation and diagnostic sets to select candidate exosomal miRNAs. Finally, receiver operating characteristic (ROC) curves were generated to evaluate the efficiency of target exosomal miRNAs in distinguishing PTC-N1 patients from PTC-N0 patients.

RESULTS

In total, 197 miRNAs were found to be differentially expressed in the testing set. Based on the qRT-PCR results, the expression of miR-6774-3p (p < 0.001) and miR-6879-5p (p < 0.001) in the PTC-N1 patients was significantly higher than that in the controls. The AUC values of plasma exosomal miR-6774-3p (0.802; 95% CI, 0.724-0.879) and miR-6879-5p (0.787; 95% CI, 0.706-0.867) and their combination (0.914; 95% CI, 0.865-0.962) were higher than those of the total miRNAs directly isolated from plasma. Moreover, the expression of exosomal miRNAs was stable after treatment with RNase A, prolonged incubation, or repeated freezing and thawing.

CONCLUSIONS

The two plasma exosomal miRNAs (miR-6774-3p and miR-6879-5p) and their combination could serve as new promising biomarkers for the diagnosis of LNM in PTC patients.

摘要

目的

在临床上,甲状腺乳头状癌(PTC)淋巴结转移(LNM)的早期诊断很重要,因为它可以辅助治疗决策,并改善预后。本研究旨在探讨血浆外泌体 miRNA 是否可以作为 PTC 患者 LNM 的潜在诊断标志物。

方法

采用 miRNA 微阵列筛选血浆外泌体 miRNA 谱。在验证集和诊断集中进行定量逆转录聚合酶链反应(qRT-PCR),以选择候选外泌体 miRNA。最后,生成受试者工作特征(ROC)曲线,以评估目标外泌体 miRNA 区分 PTC-N1 患者和 PTC-N0 患者的效率。

结果

在测试集中,共发现 197 个 miRNA 表达差异。基于 qRT-PCR 结果,miR-6774-3p(p<0.001)和 miR-6879-5p(p<0.001)在 PTC-N1 患者中的表达明显高于对照组。血浆外泌体 miR-6774-3p(AUC 值为 0.802;95%CI:0.724-0.879)、miR-6879-5p(AUC 值为 0.787;95%CI:0.706-0.867)及其组合(AUC 值为 0.914;95%CI:0.865-0.962)的 AUC 值均高于直接从血浆中分离的总 miRNA。此外,外泌体 miRNA 的表达在经 RNase A 处理、长时间孵育或反复冻融后仍稳定。

结论

两种血浆外泌体 miRNA(miR-6774-3p 和 miR-6879-5p)及其组合可作为 PTC 患者 LNM 诊断的新的有前途的生物标志物。

相似文献

1
Evaluation of plasma exosomal miRNAs as potential diagnostic biomarkers of lymph node metastasis in papillary thyroid carcinoma.评估血浆外泌体 miRNA 作为甲状腺乳头状癌淋巴结转移的潜在诊断生物标志物。
Endocrine. 2022 Mar;75(3):846-855. doi: 10.1007/s12020-021-02949-x. Epub 2021 Dec 1.
2
Plasma Exosomal miR-146b-5p and miR-222-3p are Potential Biomarkers for Lymph Node Metastasis in Papillary Thyroid Carcinomas.血浆外泌体miR-146b-5p和miR-222-3p是甲状腺乳头状癌淋巴结转移的潜在生物标志物。
Onco Targets Ther. 2020 Feb 13;13:1311-1319. doi: 10.2147/OTT.S231361. eCollection 2020.
3
Identification of exosomal miRNA biomarkers for diagnosis of papillary thyroid cancer by small RNA sequencing.通过小 RNA 测序鉴定用于诊断甲状腺乳头状癌的外泌体 miRNA 生物标志物。
Eur J Endocrinol. 2020 Jan;182(1):111-121. doi: 10.1530/EJE-19-0524.
4
Aberrant expression of five miRNAs in papillary thyroid carcinomas.五种微小 RNA 在甲状腺乳头状癌中的异常表达。
J Clin Lab Anal. 2021 Sep;35(9):e23907. doi: 10.1002/jcla.23907. Epub 2021 Jul 16.
5
Expression profile and clinical significance of microRNAs in papillary thyroid carcinoma.微小RNA在甲状腺乳头状癌中的表达谱及临床意义
Molecules. 2014 Aug 5;19(8):11586-99. doi: 10.3390/molecules190811586.
6
A Panel of Plasma Exosomal miRNAs as Potential Biomarkers for Differential Diagnosis of Thyroid Nodules.一组血浆外泌体微小RNA作为甲状腺结节鉴别诊断的潜在生物标志物
Front Genet. 2020 May 19;11:449. doi: 10.3389/fgene.2020.00449. eCollection 2020.
7
New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.甲状腺乳头状癌原发肿瘤和淋巴结转移灶的微小RNA转录组的新全球分析。
BMC Genomics. 2015 Oct 21;16:828. doi: 10.1186/s12864-015-2082-3.
8
Mapping the Molecular Basis and Markers of Papillary Thyroid Carcinoma Progression and Metastasis Using Global Transcriptome and microRNA Profiling.利用全转录组和 microRNA 谱分析绘制甲状腺乳头状癌进展和转移的分子基础和标志物。
OMICS. 2020 Mar;24(3):148-159. doi: 10.1089/omi.2019.0188. Epub 2020 Feb 19.
9
A three-microRNA panel in serum as novel biomarker for papillary thyroid carcinoma diagnosis.血清中的一个三微小RNA组合作为乳头状甲状腺癌诊断的新型生物标志物。
Chin Med J (Engl). 2020 Nov 5;133(21):2543-2551. doi: 10.1097/CM9.0000000000001107.
10
Exosomal miRNAs are potential diagnostic biomarkers between malignant and benign thyroid nodules based on next-generation sequencing.基于下一代测序的细胞外体 miRNA 是良恶性甲状腺结节之间潜在的诊断生物标志物。
Carcinogenesis. 2020 Mar 13;41(1):18-24. doi: 10.1093/carcin/bgz160.

引用本文的文献

1
Navigating thyroid cancer complexity: the emerging role of EV-derived non-coding RNAs.应对甲状腺癌的复杂性:细胞外囊泡衍生的非编码RNA的新作用
Cell Death Discov. 2025 Apr 4;11(1):142. doi: 10.1038/s41420-025-02411-1.
2
Identification of Novel Gene Signature Predicting Lymph Node Metastasis in Papillary Thyroid Cancer via Bioinformatics Analysis and in vitro Validation.通过生物信息学分析和体外验证鉴定预测甲状腺乳头状癌淋巴结转移的新型基因特征
Int J Gen Med. 2025 Mar 15;18:1463-1479. doi: 10.2147/IJGM.S502480. eCollection 2025.
3
Circulating Biomarkers of Thyroid Cancer: An Appraisal.

本文引用的文献

1
[Interpretation of the management guidelines for patients with thyroid nodules and differentiated thyroid cancer (2012 Chinese edition)].[甲状腺结节和分化型甲状腺癌患者管理指南(2012年中文版)解读]
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2013 Aug;27(16):917-20.
甲状腺癌的循环生物标志物:评估
J Clin Med. 2025 Feb 26;14(5):1582. doi: 10.3390/jcm14051582.
4
Circulating large extracellular vesicles as diagnostic biomarkers of indeterminate thyroid nodules: multi-platform omics analysis.循环大细胞外囊泡作为甲状腺结节诊断生物标志物:多平台组学分析
BJS Open. 2024 Dec 30;9(1). doi: 10.1093/bjsopen/zrae139.
5
Comparative Analysis of Metastatic Thyroid Carcinoma versus Ectopic Thyroid Carcinoma in Lateral Neck Masses without Identifiable Primary Thyroid Carcinoma.无明确原发性甲状腺癌的侧颈部肿块中转移性甲状腺癌与异位甲状腺癌的对比分析
J Clin Med. 2024 Sep 29;13(19):5819. doi: 10.3390/jcm13195819.
6
Circulating small extracellular vesicle-based miRNA classifier for follicular thyroid carcinoma: a diagnostic study.基于循环微小细胞外囊泡的 miRNA 分类器在滤泡甲状腺癌中的诊断研究。
Br J Cancer. 2024 Apr;130(6):925-933. doi: 10.1038/s41416-024-02575-0. Epub 2024 Jan 18.
7
CTC, ctDNA, and Exosome in Thyroid Cancers: A Review.循环肿瘤细胞、ctDNA 和甲状腺癌中的外泌体:综述。
Int J Mol Sci. 2023 Sep 6;24(18):13767. doi: 10.3390/ijms241813767.
8
Four differentially expressed exosomal miRNAs as prognostic biomarkers and therapy targets in endometrial cancer: Bioinformatic analysis.四种差异表达的外泌体 miRNA 作为子宫内膜癌的预后生物标志物和治疗靶点:生物信息学分析。
Medicine (Baltimore). 2023 Aug 25;102(34):e34998. doi: 10.1097/MD.0000000000034998.
9
miR-142-3p encapsulated in T lymphocyte-derived tissue small extracellular vesicles induces Treg function defect and thyrocyte destruction in Hashimoto's thyroiditis.T 淋巴细胞来源的组织细胞外小囊泡所包裹的 miR-142-3p 可诱导桥本甲状腺炎中 Treg 功能缺陷和甲状腺细胞破坏。
BMC Med. 2023 Jun 6;21(1):206. doi: 10.1186/s12916-023-02914-7.
10
Application of Nano-Delivery Systems in Lymph Nodes for Tumor Immunotherapy.纳米递送系统在肿瘤免疫治疗淋巴结中的应用
Nanomicro Lett. 2023 Jun 3;15(1):145. doi: 10.1007/s40820-023-01125-2.